Screener
Cartesian Therapeutics, Inc. RNAC Q2 2025 earnings
Reported August 7, 2025 · Before market open
Revenue$298.0KBeat by $120.4K
EPS$0.50Beat by $1.26
Revenue estimate$177.6K
EPS estimate-$0.76
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$180.0K
EPS estimate-$1.02
Versus estimates
Revenue
Q1 2026$78.0KMiss by $141.8KQ4 2025$947.0KBeat by $796.7KQ3 2025$452.0KBeat by $351.8K
Q2 2025$298.0KBeat by $120.4K
Q1 2025$1.1MBeat by $412.5KDiluted EPS
FAQ
- When did Cartesian Therapeutics, Inc. report Q2 2025 earnings?
- Cartesian Therapeutics, Inc. (RNAC) reported Q2 2025 earnings on August 7, 2025 before market open.
- What were Cartesian Therapeutics, Inc.'s Q2 2025 revenue and EPS?
- Cartesian Therapeutics, Inc. reported revenue of $298.0K and eps of $0.50 for Q2 2025.
- Did Cartesian Therapeutics, Inc. beat estimates in Q2 2025?
- Revenue beat the consensus estimate of $177.6K by $120.4K. EPS beat the consensus estimate of $-0.76 by $1.26.
- How did Cartesian Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 99.1% from $33.4M a year earlier and eps declined 7.4% from $0.54.
- Where can I find Cartesian Therapeutics, Inc.'s Q2 2025 SEC filings?
- You can read the 8-K earnings release (0001453687-25-000098) and the 10-Q periodic report (0001453687-25-000099) directly on SEC EDGAR. The filing index links above go to sec.gov.
